Johnson & Johnson Raises Earnings Forecast Amid Solid Performance
Johnson & Johnson (NASDAQ: JNJ) reported its second-quarter earnings, revealing a strong performance in its cancer drug portfolio and medical technology divisions. The company posted adjusted earnings of $2.77 per share, which, although slightly down by 1.8% compared to the previous year, surpassed analysts' expectations of $2.68.
Strong Revenue Growth
For the quarter, Johnson & Johnson achieved sales of $23.74 billion, marking a 5.8% increase from the previous year and exceeding the forecast of $22.85 billion. The company attributed this growth to operational growth of 4.6% and an adjusted operational growth rate of 3%.
Performance of Innovative Medicine
The Innovative Medicine segment saw a notable increase of 4.9%, reaching $15.20 billion in sales. Key drivers of this performance include successful products such as Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), and Rybrevant/Lazcluze in oncology. Other contributing products include Tremfya (guselkumab) and Simponi/Simponi Aria in immunology and Spravato (esketamine) in neuroscience.
Cancer Drug Sales Surge
Sales in the cancer drug category experienced a remarkable 24% growth, reaching $6.31 billion. This growth was a bright spot amidst a decline in immunology sales, which fell to $3.99 billion—a 15.4% drop. Darzalex alone contributed significantly to the cancer revenue, with sales rising 23% to $3.54 billion.
Challenges and Impacts
Despite the successes noted, the company also faced challenges, particularly with the immunology drug Stelara. Sales for Stelara fell steeply by 42.7% to $1.65 billion. Additionally, COVID-19 related impacts contributed an approximate 130 basis points to the decline.
MedTech Segment Performance
On the MedTech side, J&J's sales grew by 7.3%, reaching $8.54 billion, driven primarily by advancements in electrophysiology and cardiovascular products from Abiomed. The solid performance of these sectors highlights the company's diversified strength in healthcare.
Revised Earnings Guidance and Outlook
Moving forward, Johnson & Johnson has updated its fiscal year 2025 guidance, now expecting adjusted earnings to fall between $10.80 and $10.90 per share, up from previous expectations of $10.50 to $10.70. This new outlook is a response to an overall better-than-expected sales performance, raising the sales forecast to a range of $93.2 billion to $93.6 billion.
Market Response and Stock Performance
Following the earnings announcement, JNJ stock was reported trading higher by 1.28% to $157.15 in premarket trading. The positive response signifies investor confidence in Johnson & Johnson's growth trajectory.
Frequently Asked Questions
What were Johnson & Johnson's adjusted earnings in Q2 2025?
The adjusted earnings were reported at $2.77 per share.
How much did Johnson & Johnson's sales increase in Q2 2025?
Sales increased by 5.8% year over year, reaching $23.74 billion.
Which segment drove the highest sales growth for Johnson & Johnson?
The cancer drug segment saw a strong growth, increasing sales by 24% to $6.31 billion.
What is the new earnings guidance for Johnson & Johnson for 2025?
The revised earnings guidance is between $10.80 and $10.90 per share.
How did the market react to the earnings report?
The stock rose by 1.28% to $157.15 in premarket trading.
